 role ifosfamid cisplatin-bas chemotherapi salvag therapi patient refractori germ cell tumor prospect studi cycl etoposid ifosfamid cisplatin vip chemotherapi germ cell tumor gct patient refractori etoposide/vinblastine-bas therapi patient evalu respons patient complet respons addit patient surgic resect viabl gct median follow-up month complet respond patient remain remiss hematolog nephrotox sever durabl complet respons vip second salvag ifosfamid efficaci first-salvag therapi observ nephrotox myelotox consider design ifosfamide-cisplatin-bas regimen hematopoiet growth factor use myelotox earli use ifosfamide-bas chemotherapi nephrotox prior cisplatin trial vip first salvag relaps complet respons platinum-bas induct therapi modest proport patient durabl remiss vip second salvag need efficaci salvag therapi patient durabl complet respons